PR Newswire March 9, 2022
Prenosis

Precision medicine company will use funding to grow its industry-leading biological datasets, to advance its AI/ML capabilities to transform data into actionable insights for healthcare providers, drug developers and researchers, and to initiate the commercialization of its diagnostic and clinical decision support tools.

CHICAGO, March 9, 2022 /PRNewswire/ — Prenosis, Inc., a precision medicine company, today announced a venture investment from PACE Healthcare Capital, an early-stage investment firm committed to improving health outcomes. This investment brings total funding in the company to over $20 million, including partnerships with Foxconn, Roche Diagnostics, the Defense Threat Reduction Agency, and others.

Prenosis is leveraging machine learning algorithms trained on deep biological data and broad clinical data to create precise and comprehensive maps of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Investments, Pharma / Biotech, Precision Medicine, Trends
Related Articles:
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article